Ministry of Food and Drug Safety begins investigation into hyperlipidemia treatment that Daewon Pharmaceutical is producing on consignment

Reporter Kim Jisun / approved : 2023-10-13 03:07:11
  • -
  • +
  • 인쇄

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] The Ministry of Food and Drug Safety has launched an investigation into the cause of the report that other drugs are included in the hyperlipidemia treatment "Rosuvastatin" of Dongkuk Pharmaceutical, which is being commissioned by Daewon Pharmaceutical.

According to the Ministry of Food and Drug Safety on the 12th, a report was recently received that a digestive medicine product was found in the Rosuvastatin product box. There are two packages of Rosuvastatin, 15 pills each, one of which was for stomach medicine.

Rosuvastatin, a hyperlipidemia complex of Dongkuk Pharmaceutical, is a product commissioned by Daewon Pharmaceutical at Hyangnam Plant in Hwaseong, Gyeonggi-do.

Daewon Pharmaceutical Co. said it is conducting a full investigation into the manufacturing line that produced the product on the same day and Dongkuk Pharmaceutical Co. is recalling the product.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

Civic Groups File Complaint Against Baemin and Coupang Eats Over Alleged Misleading “One-Person Free Delivery” Promotions2025.09.19
KT Confirms Additional Victims in Unauthorized Micro-Payment Case, Faces Criticism Over Initial Response2025.09.19
KFTC Grants Conditional Approval for Joint Venture Between Shinsegae Group and Alibaba Group2025.09.19
Supreme Court Rules in Favor of NTS on U.S. Unregistered Patent Royalties2025.09.19
Korea Zinc to Cancel All Treasury Shares by Year-End, Targeting Shareholder Return Ratio Above 200%2025.09.19
뉴스댓글 >

HEADLINE

건강이 보이는 대표 K Medical 뉴스

PHOTO

많이 본 기사